rs141046414
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_152564.5(VPS13B):c.1700G>A(p.Gly567Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000672 in 1,613,758 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_152564.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VPS13B | NM_017890.5 | c.1700G>A | p.Gly567Glu | missense_variant | 13/62 | ENST00000358544.7 | NP_060360.3 | |
VPS13B | NM_152564.5 | c.1700G>A | p.Gly567Glu | missense_variant | 13/62 | ENST00000357162.7 | NP_689777.3 | |
VPS13B | NM_015243.3 | c.1700G>A | p.Gly567Glu | missense_variant | 13/18 | NP_056058.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
VPS13B | ENST00000358544.7 | c.1700G>A | p.Gly567Glu | missense_variant | 13/62 | 1 | NM_017890.5 | ENSP00000351346.2 | ||
VPS13B | ENST00000357162.7 | c.1700G>A | p.Gly567Glu | missense_variant | 13/62 | 1 | NM_152564.5 | ENSP00000349685.2 |
Frequencies
GnomAD3 genomes AF: 0.000513 AC: 78AN: 152172Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000379 AC: 95AN: 250942Hom.: 0 AF XY: 0.000420 AC XY: 57AN XY: 135594
GnomAD4 exome AF: 0.000688 AC: 1006AN: 1461468Hom.: 0 Cov.: 31 AF XY: 0.000653 AC XY: 475AN XY: 726994
GnomAD4 genome AF: 0.000512 AC: 78AN: 152290Hom.: 0 Cov.: 32 AF XY: 0.000443 AC XY: 33AN XY: 74460
ClinVar
Submissions by phenotype
Cohen syndrome Uncertain:6Other:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 12, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Dec 02, 2021 | - - |
not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 01, 2022 | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 567 of the VPS13B protein (p.Gly567Glu). This variant is present in population databases (rs141046414, gnomAD 0.08%). This missense change has been observed in individual(s) with Cohen syndrome (PMID: 25356970). ClinVar contains an entry for this variant (Variation ID: 95834). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt VPS13B protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 21, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jan 01, 2019 | - - |
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 19, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 13, 2023 | Reported previously in a patient with Cohen syndrome who was also heterozygous for a second VPS13B variant, however, clinical history and familial segregation information were not included (Farwell et al., 2015).; In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 34426522, 35690661, 25356970) - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2024 | - - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Mar 14, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 31, 2024 | Variant summary: VPS13B c.1700G>A (p.Gly567Glu) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00038 in 250942 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in VPS13B causing Cohen Syndrome (0.00038 vs 0.0025), allowing no conclusion about variant significance. c.1700G>A has been reported in the literature as a compound heterozygous genotype in at-least one individual reportedly diagnosed with Cohen syndrome following a diagnostic exome sequencing strategy (example, Farwell_2015). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 25356970). ClinVar contains an entry for this variant (Variation ID: 95834). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 03, 2022 | The c.1700G>A (p.G567E) alteration is located in exon 13 (coding exon 12) of the VPS13B gene. This alteration results from a G to A substitution at nucleotide position 1700, causing the glycine (G) at amino acid position 567 to be replaced by a glutamic acid (E). Based on data from gnomAD, the A allele has an overall frequency of 0.040% (114/282342) total alleles studied. The highest observed frequency was 0.076% (98/128904) of European (non-Finnish) alleles. This amino acid position is not well conserved in available vertebrate species. This alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
VPS13B-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 18, 2024 | The VPS13B c.1700G>A variant is predicted to result in the amino acid substitution p.Gly567Glu. This variant was documented in the compound heterozygous state with another missense variant in a patient with Cohen syndrome (Table S3, Farwell et al. 2015. PubMed ID: 25356970). This variant is reported in 0.076% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at